New Zealand markets closed

ALX Oncology Holdings Inc. (ALXO)

NasdaqGS - NasdaqGS Real-time price. Currency in USD
Add to watchlist
11.20-0.21 (-1.84%)
As of 12:03PM EDT. Market open.
Full screen
Trade prices are not sourced from all markets
Previous close11.41
Open11.45
Bid11.11 x 100
Ask11.26 x 100
Day's range11.01 - 11.45
52-week range3.94 - 17.42
Volume118,626
Avg. volume367,085
Market cap561.703M
Beta (5Y monthly)1.63
PE ratio (TTM)N/A
EPS (TTM)N/A
Earnings dateN/A
Forward dividend & yieldN/A (N/A)
Ex-dividend dateN/A
1y target estN/A
  • GlobeNewswire

    ALX Oncology Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Corporate Update

    SOUTH SAN FRANCISCO, Calif., March 07, 2024 (GLOBE NEWSWIRE) -- ALX Oncology Holdings Inc., (“ALX Oncology” or “the Company”) (Nasdaq: ALXO), an immuno-oncology company developing therapies that block the CD47 immune checkpoint pathway, today reported financial results for the fourth quarter and full year ended December 31, 2023, and provided a corporate update. “This past year proved to be a profound growth period for ALX Oncology highlighted by evorpacept’s positive results in the prespecified

  • GlobeNewswire

    ALX Oncology Announces Two Evorpacept Clinical Abstracts Accepted for Presentation at the AACR Annual Meeting

    - Investigator-initiated trial in patients with relapsed or refractory B-cell non-Hodgkin lymphoma selected for oral presentation SOUTH SAN FRANCISCO, Calif., March 05, 2024 (GLOBE NEWSWIRE) -- ALX Oncology Holdings Inc., (“ALX Oncology” or “the Company”) (Nasdaq: ALXO), an immuno-oncology company developing therapies that block the CD47 immune checkpoint pathway, today announced that two clinical abstracts have been accepted for presentation at the American Association for Cancer Research (“AAC

  • GlobeNewswire

    ALX Oncology to Present at the 42nd Annual J.P. Morgan Healthcare Conference

    SOUTH SAN FRANCISCO, Calif., Jan. 03, 2024 (GLOBE NEWSWIRE) -- ALX Oncology Holdings Inc., (“ALX Oncology”) (Nasdaq: ALXO), a clinical-stage immuno-oncology company developing therapies that block the CD47 checkpoint pathway, announced today that Jason Lettmann, Chief Executive Officer of ALX Oncology, will present a company overview at the 42nd Annual J.P. Morgan Healthcare Conference being held in San Francisco, CA on January 8th -11th, 2024. Mr. Lettmann’s presentation will take place on Mond